BioMarin's Strategic $4.8 Billion Amicus Acquisition: A Catalyst for Long-Term Growth in Rare Diseases

The biotechnology sector has long been defined by high-stakes bets on innovation, but few transactions in recent years carry the strategic and financial weight of BioMarin's $4.8 billion acquisition of Amicus Therapeutics. Announced in late 2025, the deal not only expands BioMarin's rare disease portfolio with high-growth therapies but also positions the company to deliver meaningful earnings per share (EPS) accretion over the next two years. By integrating Amicus' flagship products-Galafold® for Fabry disease and Pombiliti®/Opfolda® for Pompe disease-BioMarin is consolidating its leadership in a niche yet lucrative market while addressing long-term revenue visibility through patent extensions and operational synergies according to company statements.

Strategic Portfolio Expansion: High-Growth Assets and Market Diversification

Rare disease therapies represent a unique segment of the biotech industry, characterized by high pricing power, limited competition, and patient-centric demand. BioMarin's acquisition of Amicus adds two such therapies to its arsenal. Galafold, a substrate reduction therapy for Fabry disease, and the Pompe disease treatment duo of Pombiliti and Opfolda generated combined net product revenues of $599 million over the past four quarters. These products not only diversify BioMarin's revenue streams but also align with its core expertise in enzyme replacement therapies.

.

The strategic rationale extends beyond revenue. Amicus' global patient reach and BioMarin's manufacturing capabilities create a complementary infrastructure for scaling production and distribution. As stated by BioMarin in its press release, the acquisition "strengthens its operational footprint to drive innovation and market penetration in rare diseases". This synergy is critical in an industry where supply chain reliability and regulatory compliance are non-negotiable.

EPS Accretion: A Timeline of Financial Payoff

While strategic fit is essential, investors ultimately care about financial returns. BioMarin's acquisition is projected to be accretive to non-GAAP diluted EPS within the first 12 months post-close, with "substantial accretion" anticipated by 2027.

The 2027 milestone is particularly noteworthy. By that year, the full revenue potential of Galafold and Pombiliti/Opfolda is expected to materialize, supported by the resolution of patent litigation that now extends Galafold's U.S. exclusivity to January 2037. This exclusivity provides a clear revenue runway, reducing the risk of near-term competition. Data from MarketChameleon indicates that the acquisition is financed through a mix of existing cash and $3.7 billion in non-convertible debt, with BioMarin committed to reducing leverage to below 2.5x within two years. Such fiscal discipline underscores the company's focus on long-term value creation.

Long-Term Implications: A Model for Sustainable Growth

The Amicus acquisition exemplifies a broader trend in biotech: the consolidation of niche leaders to accelerate growth in specialized markets. By acquiring Amicus, BioMarin is not merely buying products but securing a platform for future innovation. The extended exclusivity of Galafold, combined with Amicus' pipeline of gene therapies for rare diseases, positions BioMarin to capitalize on therapeutic advancements while maintaining pricing power.

However, risks remain. The debt-financed nature of the deal requires disciplined cost management, and the rare disease market's reliance on small patient populations means any regulatory or reimbursement setbacks could disproportionately impact revenue. Yet, given the current trajectory-$599 million in recent quarterly revenues from Amicus' assets and a clear path to EPS accretion-these risks appear manageable.

Conclusion

BioMarin's $4.8 billion acquisition of Amicus Therapeutics is a masterclass in strategic biotech deal-making. By expanding its rare disease portfolio with high-growth, high-margin assets and aligning them with a robust operational infrastructure, BioMarin is poised to deliver both immediate EPS accretion and long-term shareholder value. As the industry shifts toward specialized therapies, this transaction sets a benchmark for how to balance ambition with financial prudence.